Further studies are needed for optimal dose schedule and remote effect of ACR in the treatment of ML.
对于ACR治疗淋巴瘤的合适剂量方案及远期作用尚需进一步研究。
Results It was found that the rate of recipients with non- compliance was 28.3%. They are characterized with changing the drug dose or schedule and putting off checking-up.
结果28．3%的患者没有完全依从治疗计划，主要表现为没有定时、定量服药及没有及时复诊。
A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia.
替匹法尼用一周，停一周剂量递增治疗复发性，难治性或高危髓细胞性白血病1阶段试验。
A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia.
替匹法尼用一周，停一周剂量递增治疗复发性，难治性或高危髓细胞性白血病1阶段试验。
应用推荐